A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway
Motoyuki Tsuda, Dove J. Keith, Colin J. Daniel, Carl Pelz, Katie E. Blise, Tugba Y. Ozmen, Furkan Ozmen, Kevin Hawthone, Jennifer R. Eng, Xi Li, Xiaoyan Wang, Hayley Zimny, Shamilene Sivagnanam, Konjit Betre, Nell C. Kirchberger, , Rosalie C. Sears
The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.
bioRxiv · Dec 15, 2025 · PreprintCancer Biology